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A B S T R A C TObjectives: Mifamurtide is an immune macrophage stimulant that
when added to standard chemotherapy has demonstrated survival
beneﬁt for newly diagnosed osteosarcoma. The objectives of this
study were to investigate the cost-effectiveness of adding mifamur-
tide to standard three- or four-agent chemotherapy for high-grade,
resectable, nonmetastatic osteosarcoma following surgical resection
and the issues of obtaining robust cost-effectiveness estimates for
ultra-orphan drugs, given the shortage of data. Methods: An eco-
nomic evaluation was conducted from the perspective of the UK’s
National Health Service as part of the manufacturer’s submission to
the National Institute for Health and Care Excellence. The disease
process was simpliﬁed to a transition through a series of health
states, modeled by using a Markov approach. Data to inform the
model were derived from patient-level data of Study INT-0133,
published literature, and expert opinion. The ﬁnal efﬁcacy measure
was life-years gained (LYG), and utilities were used to obtain quality-
adjusted life-years (QALYs). Results: For a 60-year time frame and a
discount rate of 3.5% for outcomes, patients receiving mifamurtide
beneﬁted from an average additional 1.57 years of life and 1.34see front matter Copyright & 2013, International S
r Inc.
1016/j.jval.2013.08.2294
001@gmail.com.
ndence to: Christopher Knight, BresMed Health SoluQALYs, compared with patients receiving chemotherapy alone, giv-
ing an incremental cost-effectiveness ratio (ICER) of £58,737 per LYG
and £68,734 per QALY. Because treatment effects were both sub-
stantial in restoring health and sustained over a very long period, the
National Institute for Health and Care Excellence changed its guid-
ance to allow a discount of 1.5% for outcomes to be applied in these
special circumstances. By using this discount factor, it was found
that patients receiving mifamurtide had an average additional 2.58
years of life and 2.20 QALYs compared with patients receiving
chemotherapy alone, resulting in an ICER of £35,765 per LYG and
£41,933 per QALY. Conclusion: Mifamurtide’s ICER is cost-effective
compared with that of other orphan and ultra-orphan drugs, for
which prices and corresponding cost-effectiveness estimates
are high.
Keywords: cost-effectiveness analysis, discount rate, NICE appraisal,
osteosarcoma, ultra-orphan.
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Osteosarcoma is the most common type of primary bone tumor
and usually occurs during childhood and adolescence [1]. Its
incidence varies with age, with an annual incidence rate of 7.3
cases per million for adolescents (aged 15–19 years) for the period
1988 to 1997 in the United Kingdom [2]. The disease has an
estimated annual incidence rate of 2.6 cases per million for
children (aged 0–14 years) for the period 1988 to 1999 [3]. These
data on osteosarcoma indicate that approximately 73 children,
adolescents, and young adults present with osteosarcoma per
year in the United Kingdom, with 58 (80%) of these individuals
having high-grade, nonmetastatic disease [4–6]. Osteosarcoma
can be considered an “ultra-orphan” disease, a term used to
describe very rare diseases, as distinct from more common
orphan diseases. The National Institute for Health and Care
Excellence (NICE) deﬁnes a disease as ultra-orphan if it has a
UK prevalence of less than 1 in 50,000 and if there are fewer than
1,000 cases per year [7].
The management of patients with osteosarcoma is complex
and aims to completely remove all clinically detectable tumorssurgically and to control microscopic metastatic disease via
systemic polychemotherapy [8]. The aim is to increase the
survival rate and prevent recurrence of the disease. The treat-
ment pathway is generally composed of neoadjuvant chemo-
therapy, followed by optimal surgery to remove the entire
primary tumor and to render the patient disease free, with a
subsequent course of adjuvant chemotherapy being adminis-
tered to target micrometastases. Young people who undergo
successful surgery for osteosarcoma are able to live full lives,
and they have a quality of life similar to that of their peers
although prosthetic limbs and endoprostheses will need to be
replaced as they grow [9].
There are currently no standard recommended combinations
of chemotherapy drugs, and the optimal treatment duration is
yet to be deﬁned [10]. There currently, however, are four chemo-
therapeutic agents with well-established efﬁcacy in treating
osteosarcoma: doxorubicin, cisplatin, high-dose methotrexate
with leucovorin rescue, and ifosfamide. Currently, 60% to 70%
of the patients having high-grade, nonmetastatic osteosarcoma
achieve long-term, disease-free survival following these three- or
four-agent neoadjuvant and adjuvant chemotherapy regimensociety for Pharmacoeconomics and Outcomes Research (ISPOR).
tions, North Church House, 84 Queen Street, Shefﬁeld S1 2DW, UK.
Fig. 1 – Markov model structure.
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drugs with proven efﬁcacy have been added to the standard
therapeutic armamentarium [8]. Various studies have suggested
that the combination of multiagent chemotherapy with biologic-
response modiﬁers and immune activators may achieve addi-
tional treatment beneﬁts [10].
Mifamurtide is an immune macrophage stimulant. It has a
marketing authorization for use in children, adolescents, and
young adults for the treatment of high-grade, resectable, non-
metastatic osteosarcoma after macroscopically complete surgical
resection, and has been safely administered together with stand-
ard adjuvant chemotherapy in patients aged between 2 and
30 years.
The largest ever completed, randomized phase III trial of
treatments for patients aged 30 years or younger with newly
diagnosed osteosarcoma initiated in 1993 was reported by Meyers
et al. [13,14]. Among the 793 patients who enrolled in the trial, 115
patients had either clinically detectable metastases or an unre-
sectable primary tumor at study entry. Of the 678 remaining
patients, 16 were considered ineligible. Among the remaining 662
patients without metastases and resectable tumors, 361 patients
were male and 301 were female. The trial results have demon-
strated a survival beneﬁt when mifamurtide is added to a
chemotherapy regimen, with the 6-year survival rates increasing
from 71% to 75% for patients on three-agent chemotherapy and
from 70% to 81% for patients on four-agent chemotherapy. For all
patients, the overall 6-year survival rate when mifamurtide is
added to a chemotherapy regimen increased from 70% to 78%
(P ¼ 0.03) [14]. The median age of patients in this trial was 13
years. The median follow-up duration for the trial, from com-
mencement of the maintenance phase, was 7.7 years while the
maximum follow-up duration was 12.25 years [14]. The clinical
trial, despite its weaknesses in standards and procedures, pro-
vided a good source of data for an ultra-orphan disease, because
of study sample size and long-term follow-up.
The cost-effectiveness of mifamurtide treatment in this
patient group has not previously been published, although the
manufacturer of mifamurtide recently made a submission to
NICE that included a cost- effectiveness analysis for mifamurtide
as an add-on to multiagent chemotherapy compared with multi-
agent chemotherapy alone [15]. The decision-analytic model and
subsequent cost-effectiveness analysis presented here formed
part of the manufacturer’s submission to NICE.
Like other ultra-orphan diseases, data shortages, due to the
limited number of clinical trials in osteosarcoma and difﬁculties
with recruiting the number of patients needed to adequately
power such a trial, mean that the level of uncertainty associated
with clinical effectiveness for mifamurtide is greater than for
drugs for prevalent diseases. Hence, this article lays out not only
how the cost-effectiveness analysis was assessed but also what
the difﬁculties were in trying to develop cost-effectiveness
models in this disease area.Methods
Model Structure
For the purposes of the economic analysis, the disease process
was formulated as a transition through a series of health states,
modeled by using a Markov approach (Fig. 1). The comparator
treatment used for assessment of the decision problem was the
three- or four-agent chemotherapy regimen alone, which repre-
sents the current UK treatment approach.
Patients entered the model in the disease-free state after
surgical resection and remain in this state unless they have a
recurrence or die. Following a recurrence, patients could moveeither to a postrecurrence disease-free state or to a postrecur-
rence disease-progression state. The ﬁrst cycle in the disease-free
state represented the chemotherapy maintenance phase, in
which all patients received adjuvant chemotherapy with or
without mifamurtide. This cycle had a length of 9 months.
Thereafter, cycles had a length of 6 months. Patients moved
among states during each cycle. Once patients entered the
disease-progression state, the model made the assumption that
they remained there until death. Patients in the disease-free
health state at the end of the trial period (12.25 years) were
assumed to have a mortality rate equivalent to that of the general
population. The model used estimates of effectiveness, costs, and
health-state values in these health states to model progression of
disease and cost-effectiveness over time. Costs and outcomes
were discounted at 3.5% per annum, in line with NICE guidance
[16].
As mifamurtide is indicated for children, adolescents, and
young adults, with the potential for a long life expectancy, a time
horizon of 60 years was considered as the base case. Other time
horizons were considered in the sensitivity analysis.
The number of patients exiting the disease-free state at the
end of each 6-month cycle was governed by time-dependent
transition probabilities of recurrence and death. Actual patient
numbers, from patient-level data collected in the trial, were used
to compute transition probabilities for each 6-month period, with
patients lost to follow-up attributed to a health state based on the
transition probabilities derived from those patients not lost to
follow-up.
Patients who experienced a recurrence in the trial were not
routinely followed up, and those who were lost to follow-up were
reported as withdrawals. The clinical literature reported that the
risk of survival postrecurrence was dependent on the site of
recurrence, and that site was a determinant for achievement of
disease- free status and survival postrecurrence. Of those
patients in the trial whose disease did recur, approximately 85%
of the patients in both treatment groups experienced disease
recurrence at a pulmonary location or other (pleural, regional,
radiation ﬁeld, mediastinal, lymph node) sites. In the trial,
approximately 50% of the patients had pulmonary metastases
only.
Because the literature indicated that the risk of death post-
recurrence was different for patients achieving disease-free or
non–disease-free status postrecurrence, it was considered impor-
tant to factor literature ﬁndings into the model and include an
analysis of events postrecurrence.
Data from Ferrari et al. [17] were used to calculate remission
rates from surgery or a combination of surgery and second-line
chemotherapy. The Ferrari et al. study reported ﬁndings from
162 patients with recurrent osteosarcoma (75% of whom had
lung metastases) who received ﬁrst-line treatment, including
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 2 3 – 1 1 3 2 1125resection of the primary lesion and adjuvant chemotherapy with
methotrexate, doxorubicin, cisplatin, and ifosfamide.
The estimates for survival postrecurrence also were taken
from Ferrari et al. [17]. In that study, for those patients who failed
to achieve complete surgical remission, postrecurrence survival
did not differ according to the site of ﬁrst recurrence but was
inﬂuenced by the use of chemotherapy. The postrecurrence 1-
year survival rate was 53% for patients who received chemo-
therapy versus 12% for patients who did not. Within 2 years, all
patients were deceased. Postrecurrence survival rates at 1 year,
18 months, and 2 years were assumed to be 0.4, 0.18, and 0,
respectively [17]. In patients who achieved complete surgical
remission, postrecurrence survival was inﬂuenced by both
relapse site and the length of the relapse-free interval (r24 or
424 months). The 5-year postrecurrence survival rates were
reported as 20% (95% conﬁdence interval [CI] 9%–30%) for recur-
rences occurring within 24 months or less and 60% (95% CI 46%–
74%) for recurrences occurring after 24 months [17]. These rates
were used in the model. Postrecurrence mortality rates were set
to those of the age-matched general population if patients were
disease free for 5 years.
Patients in each health state were attributed health-state
utility values and costs within each cycle. A half-cycle correction
was applied in the model.
Clinical Effectiveness
Clinical effectiveness data were taken from the randomized
clinical trial reported by Meyers et al. [14], a primarily US-based,
multicenter, phase III, open-label clinical trial. Given that this
was the only signiﬁcant trial of mifamurtide in the appropriate
patient population, it was the only source for effectiveness
evidence (e.g., extended evidence or mixed-treatment compar-
ison would not be relevant). In brief, the trial recruited 678
patients with nonmetastatic osteosarcoma whose primary
tumors were considered to be resectable, which included 16
patients who were deemed ineligible in the Meyer et al. study
[14]. Although the true intention-to-treat population was 678
patients, compared with the trial reporting 662 patients in Meyer
et al. [14], the study ﬁndings and conclusions were the same
irrespective of inclusion or exclusion of ineligible patients. All
patients were randomized at study entry to one of four groups
(regimen A: methotrexate, doxorubicin, and cisplatin; regimen
Aþ: regimen A plus mifamurtide; regimen B: methotrexate,
doxorubicin, and ifosfamide; and regimen Bþ: regimen B plus
cisplatin and mifamurtide). Mifamurtide administration was
delayed until the maintenance (adjuvant) phase (week 12) follow-
ing tumor resection. Detailed patient enrolment criteria and
clinical results are described elsewhere [14]. In the base-case
analyses presented here, data have been pooled across the two
mifamurtide arms (regimens Aþ and Bþ) and across the two
nonmifamurtide arms (regimens A and B) of the trial.
The overall survival data for the intention-to-treat population
in patients with nonmetastatic osteosarcoma in the trial showed
that after a median follow-up of 7.7 years, adding mifamurtide to
chemotherapy statistically signiﬁcantly improved overall survival
compared with chemotherapy alone (P ¼ 0.0313). The hazard
ratio for overall survival favored mifamurtide (hazard ratio ¼
0.72; 95% CI 0.53–0.98), with a 28% reduction in the risk of death.
Cost of Adjuvant Chemotherapy
In the trial, the total doses of methotrexate, cisplatin, and
doxorubicin administered during induction and maintenance
were identical in regimens A and B. The timings of cisplatin
use between regimens A and B, however, were different [13,14].
Patients assigned to receive mifamurtide in the maintenancephase received twice-weekly intravenous infusions for 12 weeks,
followed by once-weekly intravenous infusion for an additional
24 weeks, for a total of 48 infusions over 36 weeks. The number of
doses received in the trial by each patient varied considerably—in
fact, only 53% of the patients received the full 48-dose mifamur-
tide regimen. This is not unusual for pediatric experimental
research, in which age is one of the most commonly cited
predictors of early study dropout [18], and especially when
considering the extension of the already signiﬁcant standard
treatment regimen with the introduction of mifamurtide.
Because the efﬁcacy data in the model are based on the number
of actual mifamurtide doses administered and not the assumed
48 doses, the model default was set to the actual average of
mifamurtide doses administered. A weighted average of 38
mifamurtide doses was calculated from trial data, and this
number was used in the model’s base case. Table 1 summarizes
the unit costs for each of the agents in the adjuvant chemo-
therapy regimen, together with the unit cost of a mifamurtide
dose.
Adjuvant chemotherapy in the United Kingdom is adminis-
tered on an inpatient basis. According to the trial’s dosing schema
and expert opinion, a set number of inpatient days were attributed
to each chemotherapy drug that also accounted for leucovorin
rescue with methotrexate and mesna administration plus 24-hour
rehydration postdose with ifosfamide. It was estimated that
delivery of regimen A and regimen B (adjuvant chemotherapy)
required 56 and 68 inpatient days, respectively. The trial’s dosing
schema also indicated that a proportion of mifamurtide doses
required an outpatient visit, with no other adjuvant agent being
scheduled for administration on these days. Because UK dosing
schedules in clinical practice may vary from the dosing schedule
in the trial, it was estimated that up to 30% of the doses may
require an outpatient visit [19]. The average number of additional
mifamurtide outpatient visits required was estimated to be 7, as
calculated from the actual patient distribution of mifamurtide
doses received. Uncertainty around this estimate was explored in
a sensitivity analysis. Table 1 summarizes the unit costs associ-
ated with inpatient and outpatient visits for the delivery of
adjuvant chemotherapy and mifamurtide.Adverse Events
Only clinically relevant, treatment-differentiating adverse events
were considered in the economic evaluation, that is, only those
adverse events with a potentially higher incidence rate in the
mifamurtide treatment arm than in the no-mifamurtide arm.
Such events included infusion reactions, such as fevers and
chills, and hearing loss. Clinical expert opinion considered the
higher incidence of hearing loss in the mifamurtide group as a
data anomaly, because hearing loss generally is associated with
cisplatin use and the rates in the trial were consistent with those
reported for cisplatin. In addition, differences in hearing loss
were observed only in the A versus Aþ arms (5% vs. 16%), not the
B versus Bþ arms (10% vs. 8%), adding further evidence that this
was a data anomaly. Therefore, hearing loss was not included in
the base-case analysis but was explored in a sensitivity analysis
(mifamurtide: 15%; no mifamurtide: 8%). Cost estimates (Table 2)
were derived from National Health Service reference costs. Expert
opinion was used when estimating resource use for patients with
hearing loss. Within 6 months of completion of the maintenance
phase, patients experiencing hearing loss had a hearing aid ﬁtted
and a postﬁtting assessment. Thereafter, patients were assumed
to have annual follow-up visits with an audiology department
until the end of the 4-year postmaintenance phase, when a
replacement hearing aid is ﬁtted. Annual assessments continued
after this replacement ﬁtting.
Table 1 – Adjuvant chemotherapy and mifamurtide medication and resource costs.
Adjuvant chemotherapy and mifamurtide medication costs during the maintenance phase
Agent Dose Number of doses in
regimen A
Number of
doses in
regimen B
Unit cost per dose (£) Source
Doxorubicin 25 mg/m2 per day 12 12 102.00 BNF 56 [20]
Cisplatin 120 mg/m2 2* 4 100.44 BNF 56 [20]
Methotrexate 12 g/m2 8 8 1369 BNF 56 [20]
Ifosfamide 1.8 g/m2 per day – 15 72.52 BNF 56 [20]
Mifamurtide 2 mg/m2 38 38 2375 BNF 56 [20]
Adjuvant chemotherapy and mifamurtide administration costs
Description Frequency Unit cost
(£)
Source
Inpatient visit to deliver adjuvant chemotherapy
treatment in regimen A (ﬁrst visit)
1
307
NHS reference cost 2007–08 (1SB14Z) [21]
Inpatient visit to deliver adjuvant chemotherapy
treatment in regimen A
55
220
NHS reference cost 2007–08 (SB15Z) [21]
Inpatient visit to deliver adjuvant chemotherapy
treatment in regimen B (ﬁrst visit)
1
307
NHS reference cost 2007–08 (1SB14Z) [21]
Inpatient visit to deliver adjuvant chemotherapy
treatment in regimen B
67
220
NHS reference cost 2007–08 (SB15Z) [21]
Outpatient visit for mifamurtide administration (30% of
the mifamurtide doses are administered alone and
require extra outpatient visit)
7
189
NHS reference cost 2007–08 (O/P specialty code
370) [21]
Pharmacy time to prepare a mifamurtide dose 1 h per dose
50
Clinical estimate
NHS, National Health Service.
 Two doses of cisplatin were administered during the induction phase for regimen A.
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In the absence of resource-use data from the clinical trial,
estimates of health care resource use were obtained from expert
opinion and the European and American Osteosarcoma I study
protocol [22].
In the model, resource use and monitoring costs were differ-
entiated on the basis of health state, and the cost of routine
monitoring was applied for each patient at the appropriate cycle,
provided that the patient survived (Table 2). Routine monitoring
costs ceased to be applied when patients moved from the
disease-free state. As in clinical practice, routine monitoring of
patients for weight assessment, clinical examination, thyroid
function tests, and blood chemistry continued up to and beyond
12 years. Routine chest x-rays commenced after the ﬁrst 4
months of the postmaintenance phase and were performed at
every visit up to the end of year 5.
In the model, a transition to the recurrence state was condi-
tional on a patient having no evidence of disease before recur-
rence. Therefore, transitions to this state were always from the
disease-free state. Patients suspected of having a relapse from
their routine chest x-ray performed during the disease-free state
were considered asymptomatic. Patients stayed in the recurrence
state for one cycle only before moving to one of the postrecur-
rence states. In this state, they incurred diagnostic costs (com-
puted tomography scan, isotope bone scan, magnetic resonance
imaging, blood tests, and central line insertion) as well as costs of
additional surgery or chemotherapy (per clinical opinion).
Second-line chemotherapy was assumed to be ifosfamide and
etoposide administered on an inpatient basis for an average of
ﬁve cycles (per clinical opinion).
Table 2 outlines the costs associated with recurrence diag-
nosis and surgery. Two outpatient visits for diagnostic evaluationand a further 3-day elective inpatient stay for surgery were
assumed. These costs were applied for each patient at the point
of recurrence in the model.
Patients were assumed to have palliative care when in the
postrecurrence disease-progression state. No evidence could be
found to quantify the resource utilization for palliative care in
patients with osteosarcoma in the United Kingdom. For the
economic evaluation, the cost of palliative care (£3481) for patients
in disease progression was assumed to be the average of the mean
National Health Service cost across all cancers [25]. Palliative care
costs were incurred at the point of death in the model.Health-Related Quality of Life
Although cost-utility analysis is the framework of economic
evaluation preferred by UK health technology assessment bodies,
no cost-utility analyses have been conducted in osteosarcoma.
There have been no suitable utility values published for adoles-
cents with the disease. In the absence of trial-based or published
estimates, the utilities used in the model were obtained from a
review of NICE appraisals of cancer technologies, including treat-
ments of colon, colorectal, renal cell, and prostate cancer,
myeloid leukemia, and glioma, with 0.85 being representative of
the health-related quality of life of patients who are deemed as
disease free following cancer treatment. The speciﬁc base-case
utilities and rationale for the choice of utility for each health state
are provided in Table 3, with alternative scenarios that were
investigated in sensitivity analysis for impact on cost-
effectiveness.
The disutility for hearing loss was not captured by the health-
state utilities outlined in Table 3 and hence has been included as
an additional disutility factor across the health states for patients
Table 2 – Monitoring, resource, and adverse event costs.
Frequency of routine monitoring in the disease-free state
Timing of visit following the
maintenance phase
Frequency
Up to 4 mo Monthly
5 mo to 1 y Every 2 mo
Year 2 Every 3 mo
Years 3 and 4 Every 4 mo
Year 5 Every 6 mo
Year 6 onwards Once a year (the EURAMOS 1 study [22] required twice yearly monitoring but a UK expert opinion noted that this is not typical UK practice)
Recurrence diagnostic and surgery resources and unit costs
Resource Frequency Unit cost (£) Source
Diagnosis
CT scan 1 116 NHS reference cost 2007–08 [21] (RA11Z)
MRI 1 214 NHS reference cost 2007–08 [21] (RA02Z)
Isotope bone scan 1 164 NHS reference cost 2007–08 [21] (RA36Z)
Outpatient visits 2 189 NHS reference cost 2007–08 [21] (O/P specialty code 370)
Inpatient visit for central line
insertion
1 4288 NHS reference cost 2007–08 [21] (EA36B, catheter 18 y and under)
Surgery
Salvage surgery (pulmonary)
(3-d inpatient stay)
1 1797 NHS reference cost 2007–08 [21] Equal to average of three elective inpatient HRGs (DZ09A, DZ09B, and DZ09C)
Salvage surgery
(nonpulmonary) (3-d
inpatient stay)
1 2194 NHS reference cost 2007–08 [21] Equal to average of three elective inpatient HRGs (HD36A, HD36B, and HD36C)
Annual cost of endoprosthesis NA 1091 Cost derived from Grimer [23], cost uplifted to 2006 via the consumer price index [24]
Costs of treatment-differentiating adverse events during maintenance
Adverse event Mifamurtide
incidence (%)
No
mifamurtide
(%)
Treatment during the
maintenance phase
Unit
cost (£)
Source
Infusion-related inﬂuenzalike
symptoms (chills and fever)
98 0 Paracetamol 0.5–1 g every 4–6 h
to a maximum of 4 g daily
1.91 BNF 56 [21]: paracetamol 500 mg. Net price: 16 tablets ¼ £0.17; 32
tablets ¼ £0.46; 100 tablets ¼ £1.91 (100 tablets per patient)
Hearing loss (objective or
subjective)
15 8 One audiometry assessment 50.00 NHS reference cost 2006–07 [21] (AS1A: ﬁtting of hearing aids
and counseling assessment)
CT, computed tomography; HRGs, Healthcare Resource Groups; MRI, magnetic resonance imaging; NA, not applicable; NHS, National Health Service.
V
A
L
U
E
IN
H
E
A
L
T
H
1
6
(2
0
1
3
)
1
1
2
3
–
1
1
3
2
1127
Table 3 – Utilities for modeling.
Disease state Base-case
utility
Source/rationale
Disease progression 0.39 NICE HTA review. The HTA review provided an estimate of 0.44 for the disease progression
to death category, which was adjusted by the –12% correction factor, as given below
Disease free 0.85 NICE HTA review
Recurrence 0.61 NICE HTA review. The HTA review provided an estimate of 0.69 for the disease-progression/
recurrence category. A correction factor of –12% was applied, on the basis of the ratio for the
average utility for the disease-free state in the EQ-5D questionnaire survey and Alessi et al.
[27] (0.75) and the disease-free category in the NICE HTA review (0.85)
Disease-free
postrecurrence
0.85 Assumed to be the same as the disease-free value
Disease progression
postrecurrence
0.39 Assumed to be the same as the disease-progression value.
Death 0
EQ-5D, EuroQol ﬁve-dimensional; HTA, health technology assessment; NICE, National Institute for Health and Care Excellence.
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contained a disutility factor of –18% for hearing loss in patients
with cancer [26], although no such study exists speciﬁcally for
patients with osteosarcoma. This factor represents a signiﬁcant
decrement in utility and is associated with the need for a hearing
aid. The factor, however, may be an overestimate for hearing loss
due to osteosarcoma-related chemotherapy; clinical opinion did
not suggest that any hearing impairment in patients with
osteosarcoma always resulted in a hearing aid and a resulting
disutility of 0.18 [15]. Given the absence of data for osteosarcoma,
this value was considered to be a conservative estimate and was
assessed in a sensitivity analysis.Sensitivity Analysis
To test the uncertainty of some of the model assumptions, a
series of univariate analyses were performed on several param-
eters. Costs could vary by 40%, excluding drug costs, which were
ﬁxed. Mortality rates postrecurrence, as well as surgery and
second-line chemotherapy at recurrence, were assumed to vary
within their 95% CIs. Recurrence rates and quality-of-life utility
values varied between their 95% CIs, derived from assuming that
each utility value followed a beta statistical distribution. The total
number of individuals used to derive the utility values was based
on the number of individuals in the Alessi et al. [27] study.
Discounting was varied between 0% and 6%.
In the probabilistic analysis, key model parameters were
sampled from parametric distributions to generate 10,000 esti-
mates of the costs and effects in each arm, from which the
probabilistic mean incremental cost-effectiveness ratio (ICER)
and 95% CIs were estimated. The transition probabilities ofTable 4 – Base case discounted per patient mean costs a
Results Mifamurtide (£) No m
Mifamurtide drug cost 91,189
Adjuvant chemotherapy cost 26,205
Resource-use cost 6,458
Total costs 123,852
Life-years 19.70
Cost per life-years gained
QALYs 16.72
Cost per QALY
QALY, quality-adjusted life-year.recurrence and death from the disease-free state, which were
derived from the trial data, were sampled from a Dirichlet
distribution, using a series of conditional beta distributions, a
method that corresponds to the decomposition of a multibranch
node into a series of conditional dichotomous nodes [28]. Tran-
sition probabilities to and from the postrecurrence disease states
and utility weights were sampled from beta distributions derived
from patient numbers [17]. Costs were sampled from a gamma
distribution deﬁned by the mean and assuming a standard error
of one ﬁfth of the mean [29].
Outputs from the probabilistic sensitivity analysis were used
to generate cost-effectiveness acceptability curves, to assess the
probability of cost-effectiveness at different thresholds repre-
senting UK society’s willingness to pay.Results
Base-Case Results
The base-case results presented in Table 4 compare maintenance
chemotherapy plus adjuvant mifamurtide treatment (both regi-
mens A and B) to maintenance chemotherapy alone. The base-case
results were based on a time horizon of 60 years. Over this time
frame, patients receiving mifamurtide beneﬁted from an average
additional 3.95 years of life and 1.34 quality-adjusted life-years
(QALYs) than did patients receiving maintenance chemotherapy
alone. The drug cost attributable to mifamurtide was £91,189; there
also was an increased overall use cost of £1,181 for patients
receiving mifamurtide, mainly due to the increased number of
outpatient visits required for the administration of mifamurtide.nd effects.
ifamurtide (£) Mifamurtide vs. no mifamurtide (£)
0 91,189
26,205 0
5,277 1,181
31,481 92,371
18.13 1.57
58,737
15.38 1.34
68,734
Table 5 – New base case based on a discount rate of 1.5% for health effects and 3.5% for costs.
Results Mifamurtide (£) No mifamurtide (£) Mifamurtide vs. no mifamurtide (£)
Mifamurtide drug cost 91,189 0 91,189
Adjuvant chemotherapy cost 26,205 26,205 0
Resource-use cost 6,458 5,277 1,181
Total costs 123,852 31,481 92,371
Life-years 29.53 26.95 2.58
Cost per life-year gained 35,765
QALYs 25.07 22.87 2.20
Cost per QALY 41,933
QALY, quality-adjusted life-year.
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murtide over maintenance chemotherapy alone was estimated to
be £68,734 per QALY and £58,737 per life-year gained.
Sensitivity Analysis: The Discount Rate
Cost-effectiveness estimates were most sensitive to the discount
rate for outcomes because for a young population, the long-term
beneﬁts of mifamurtide treatment were heavily discounted. That
is, the majority of the treatment costs were incurred in the ﬁrst
year of the model, but the clinical outcomes were realized over
the entire time horizon.
NICE [16] currently recommends an annual discount rate of
3.5% for both costs and outcomes for the reference case. After a
reappraisal of mifamurtide, however, NICE issued further
guidance on discounting of health beneﬁts in special circum-
stances. The new guidance by the NICE Appraisal Committee
now states that “where the Appraisal Committee has consid-
ered it appropriate to undertake sensitivity analysis on the
effects of discounting because treatment effects are both
substantial in restoring health and sustained over a very long
period (normally at least 30 years), the Committee should apply
a rate of 1.5% for health effects and 3.5% for costs.” This
category applies to mifamurtide; hence, a new base case was
developed by using these new discount rates. The results are
presented in Table 5.
Using the new discount rates as recommended by NICE, a
sensitivity analysis showed that patients receiving mifamurtide
beneﬁted from an average additional 2.20 QALYs than did
patients receiving maintenance chemotherapy alone. This
resulted in an ICER of £41,933 per QALY and £35,765 per life-
year gained.Table 6 – Univariate sensitivity analysis.
Variable
Low
Discount—outcomes 0%
Discount—cost 0%
Utility—disease-free 0.75
Utility—disease-progression 0.25
Utility—disease recurrence 0.46
Adjustment for multiple vials* NA
Cost of an outpatient visit for mifamurtide dosing £113
Hearing loss None
Time frame 40 y
NA, not applicable.
 Increase in the number of mifamurtide doses.Sensitivity Analysis: Other Parameters
In the univariate analysis, the results were sensitive to the
health-state utility for the disease-free state and the number of
doses of mifamurtide given to the patient. When the utility was
decreased from its default value of 0.85 to 0.75, the resulting ICER
was £47,582 per QALY. Changing the time frame of the analysis to
40 years also had a noteworthy effect on the ICER, increasing it to
£55,586 per QALY.
The sensitivity analysis also explored the costs applied to the
management of hearing loss, as well as its impact on health-
related quality of life. Incorporating the adverse event of hearing
loss assumed that 15% of the patients receiving maintenance
chemotherapy plus mifamurtide and 8% of the patients receiving
chemotherapy alone had hearing impairment. This assumption
affected both the costs and QALYs because a utility decrement of
18% was applied to these patients, along with extra resource
costs. The resulting discounted ICER increased to £51,545 per
QALY. The univariate sensitivity results are presented in Table 6.
Sensitivity analysis indicated that the ICER was relatively
insensitive to other inputs explored.
The uncertainty about the effect of interaction between
ifosfamide and mifamurtide on the trial results was explored
in a subgroup analysis. The sensitivity analysis results for the
treatment groups with and without ifosfamide underscored
the importance of this question in regard to the cost-
effectiveness of mifamurtide. For regimens Aþ versus A,
results for the base-case scenario were £103,343; for regimens
Bþ versus B, results for the base-case scenario were £26,872.
The Study INT-0133, however, was not powered to compare
regimens Aþ versus A and Bþ versus B separately and overall
survival differences were not statistically signiﬁcant for theValue Results
High Low High
6% £26,995 £112,536
6% £42,009 £41,925
0.94 £47,582 £39,584
0.54 £41,937 £41,929
0.75 £41,877 £42,024
1.05 NA £44,003
£265 £41,680 £42,187
18% NA £51,545
NA £55,586 NA
Fig. 3 – Cost-effectiveness acceptability curve for
mifamurtide versus no mifamurtide. CE, cost-effectiveness;
QALY, quality-adjusted life-year; sims, simulations;
Fig. 2 – Simulations of mean incremental total costs versus
beneﬁts for mifamurtide versus no mifamurtide (outcome
discount rate ¼ 1.5%). QALY, quality-adjusted life-year.
V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) 1 1 2 3 – 1 1 3 21130two subgroups. Thus, as NICE concluded, the more appropri-
ate comparison was the combined analysis of all the Study
INT-0133 data [15].
The probabilistic analysis of the base case suggested that
there was a 23.5% probability that the ICER would fall below a
threshold value of £30,000 per QALY and a 62.5% probability
that it would fall below a threshold value of £50,000 (see Figs. 2
and 3).Table 7 – Some ultra-orphan drugs in current use [30].
Product Condition
Agalsidase beta (Fabrazyme) Fabry’s
Imiglucerase (Ceredase) Gaucher’s (types I and III)
Laronidase (Aldurazyme) Mucopolysaccharidosis (type 1)
Miglustat (Zavesca) Gaucher’s (type I)
Nonacog alfa (BeneFIX) Hemophilia B
Iloprost (Ventavis) Primary pulmonary hypertension
Mifamurtide High-grade, resectable, nonmetastat
osteosarcoma after macroscopica
complete surgical resection
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-yeDiscussion
We have used data from a trial conducted in the 1990s to evaluate
the cost-effectiveness of mifamurtide as an add-on to multiagent
chemotherapy versus multiagent chemotherapy alone for
patients with high-grade, resectable, nonmetastatic osteosar-
coma after macroscopically complete surgical resection. We also
have attempted to identify all published data that could inform
the model, particularly in relation to postrecurrent health states.
The model presented here is the ﬁrst economic evaluation
published for osteosarcoma, an ultra-orphan disease.
The results were highly sensitive to the discount rate for
outcomes, given that the majority of the treatment costs are
incurred within the ﬁrst year of the model but that the clinical
outcomes are realized over the entire model time horizon. Using
the standard NICE discount rate of 3.5% for outcomes, the
incremental beneﬁt of 3.95 life-years and 1.34 QALYs due to the
addition of mifamurtide, coupled with the incremental costs of
£92,371, resulted in an ICER of £68,734 over the 60-year time
frame. Following new guidance from NICE, however, in the
special case of mifamurtide, a discount rate of 1.5% is recom-
mended for outcomes, which resulted in an ICER of £41,933. The
ICER is favorable and represents a cost-effective option when
compared with other orphan and ultra-orphan drugs, for which
prices and the corresponding cost-effectiveness estimates are
high (see Table 7) [30].
There has always been some debate over the rates of dis-
counting that should be used in a cost-effectiveness analysis,
whether the discounting should be uniform or differential, and
whether discount rates should vary over time [31]. Opponents of
using a uniform discounting approach have argued that using
uniform discounting assumes that the relationship between costs
and life-years (and hence QALYs) remains independent of time,
which may not necessarily be the case. Another argument for
differential discounting, supporting a view that health beneﬁts
should not be discounted at all, was the possibility of inadvertent
double discounting of beneﬁts [32,33]. These authors argued that
health-related outcomes such as quality of life may already have
been incorporated into an individual’s time preference, especially
when utility is measured by using the time trade-off or standard
gamble method. Thus, they conclude, if health outcomes also are
discounted in the future, the value of future beneﬁts of an
intervention will be underestimated.
The most commonly used method of discounting adopted by
the reimbursement authorities, such as NICE, is uniform dis-
counting, using a constant nonzero discount rate (commonly 3%
or 5%). Severens and Milne [31] argued that this method leads
to prioritization of immediate treatment at the expense ofPrevalence Preliminary estimated ICER
(£ per QALY)
200 203,009
270 391,244
130 334,880
270 116,800
350 172,500
100 23,324
ic
lly
58 68,734 (original base case) 41,933 (using
1.5% outcomes discount rate)
ar.
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measures, including some evidence-based screening and pedia-
tric vaccination programs. Because osteosarcoma primarily
affects the young, this argument is valid in the case of mifamur-
tide. Severens and Milne [31], however, also stated that variable
discounting rates of both costs and beneﬁts can be adopted as a
methodology without violating the theoretical principles of uni-
form discounting. A variable discounting approach for health
outcomes, when compared with a uniform discount rate over
time, would clearly support health care programs that incur costs
now but have future health beneﬁts. Such an example would be
vaccines, where there is typically a long time lag between
vaccination and its beneﬁt (avoidance of later illness), a scenario
similar to mifamurtide treatment. The discount rate used in an
economic evaluation of a vaccine is particularly important, and
such analyses often incorporate 1.5% and 0% discount rates [34].
The rarity of a disease means that development costs must be
recouped from drug sales to a limited number of patients world-
wide, with consequently high per-patient acquisition costs [35].
This means, however, that it is virtually impossible for these
treatments to meet conventional criteria for cost-effectiveness.
Many researchers have argued for a special status for ultra-
orphan and orphan drugs, in terms of applying a different value
to health gain obtained by patients with those conditions [35–37].
Furthermore, doubts have been expressed about whether stand-
ard methods of health technology assessment are entirely suit-
able for the evaluation of drugs for rare diseases [38]. A number of
options to address resource allocation issues for ultra-orphan
drugs have been suggested, including more focus on the societal
value of these drugs, different mechanisms of funding, and QALY
weighting according to disease prevalence. The literature also
suggested that a majority of the general population had a
preference for putting a greater weight on health gains accrued
by children, by severely ill patients, and by the socioeconomically
disadvantaged [39].
A number of researchers, however, have argued that awarding
a special status to ultra-orphan drugs may impose substantial
and increasing costs on the health care system, with these costs
invariably being borne by patients with more common diseases
[40]. Other potentially relevant issues that remain outside the
cost-effectiveness framework include the poor prognosis for
patients with osteosarcoma and the absence of other effective
treatment options.
Obtaining accurate cost-effectiveness estimates is often more
difﬁcult for ultra-orphan drugs than for others drugs, and this can
produce considerable uncertainty regarding cost-effectiveness.
The evidence base for orphan drugs is considered to be too
sparse to allow estimates of cost-effectiveness. The clinical
evidence informing our analysis was derived from one large,
prospective, randomized, phase III trial. Although the trial gen-
erally was well conducted, there were several methodological
issues raised by NICE, but none was considered substantial
enough to decline approval of the product [15]. These included
delayed administration or nonadministration of mifamurtide and
an imbalance in histological response to neoadjuvant therapy
between treatment groups, the disparity being particularly pro-
nounced for patients assigned to regimen Aþ, who had a greater
proportion of tumors showing a poor histological response,
which, as NICE commented, may have disadvantaged mifamur-
tide. The effect of these methological issues raised by NICE has
led to further uncertainty, and the single source of data for
efﬁcacy parameters means that any biases within the trial will
be reﬂected in the cost-effectiveness analysis presented here.
Although recurrence was an end point in clinical trial, infor-
mation pertaining to a patient’s disease-free or disease-
progression status after recurrence (with the exception of death)
was not collected consistently in the study. Assumptionsregarding resource and outcomes postrecurrence were derived
from a single source [17] in the absence of other available data.
Again, any biases within this study will be reﬂected in the cost-
effectiveness analysis presented here.
There is an absence of published data on the utilities asso-
ciated with the treatment of osteosarcoma. In our analysis, we
have used data from our review of the utilities used in independ-
ent economic models developed by the NICE Assessment Group
for published or ongoing cancer technology appraisals. We
believe that this is a comprehensive approach to ascertaining
utilities in this ultra-orphan disease, where there is minimal
information. Other health-related quality-of-life beneﬁts, how-
ever, may not have been adequately captured in the estimated
gains used in the QALY calculation—such as the utility of carers,
particularly for patients for whom treatment is not successful.Conclusions
This is the ﬁrst economic cost-effectiveness analysis of mifamur-
tide for the treatment of high-grade, resectable, nonmetastatic
osteosarcoma. By using data from Study INT-0133, the model
demonstrated that patients with newly diagnosed, high-grade,
resectable, nonmetastatic osteosarcoma experienced improved
survival outcomes when mifamurtide was added to a three- or
four-agent chemotherapy. Such a beneﬁt is particularly impor-
tant, given the huge unmet medical need and the lack of progress
in improving outcomes for patients with osteosarcoma over the
last 20 years. While results were highly sensitive to the discount
rate for outcomes, given the long time horizon of beneﬁt accrual,
mifamurtide’s ICER is favorable and represents a cost-effective
option compared with other orphan and ultra-orphan drugs, for
which prices and the corresponding cost-effectiveness estimates
are high. Obtaining accurate cost-effectiveness estimates, how-
ever, is often more difﬁcult for ultra-orphan drugs than for other
drugs, which can produce considerable uncertainty regarding the
cost-effectiveness.
Further research is required to address the parameter uncer-
tainty of the analysis presented here, as well as to understand
and address the shortcomings of economic evaluations of ultra-
orphan drugs, particularly those used to treat childhood diseases.
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